 HAYWARD, Calif.--BUSINESS WIRE--Arcus Biosciences, Inc. NYSE:RCUS, an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Companys Board of Directors granted ten new employees options to purchase a total of 343,000 shares of the Companys common stock at an exercise price per share of 21.53, which was the closing price on November 9, 2020. The stock options were granted pursuant to the Company 